An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Breast Neoplasms
Interventions
DRUG

Dexamethasone

Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.

DRUG

Trabectedin

Trabectedin 1.3 mg/m\^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.

Trial Locations (33)

Unknown

Sedona

Denver

Torrington

Indianapolis

Westminster

Minneapolis

Columbia

Kansas City

St Louis

Amsterdam

New York

Bedford

Dallas

Houston

San Antonio

Tyler

Norfolk

Salem

Seattle

Spokane

Yakima

Bourdeaux

Marseille

Saint-Herblain

Strasbourg

Villejuif

Jerusalem

Rehovot

Tel Aviv

Tel Litwinsky

Lubin

Rybnik

Szczecin

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PharmaMar

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY